Helix BioPharma Corp. (HBPCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Helix BioPharma Corp. (HBPCF) trades at $1.71 with AI Score 45/100 (Grade C). Helix BioPharma Corp. Market cap: $131M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for HBPCF: HBPCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HBPCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HBPCF: 2/3 scored disciplines lean bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Helix BioPharma Corp. (HBPCF) Healthcare & Pipeline Overview
Helix BioPharma Corp., an immune-oncology company based in Canada, is focused on the development of targeted therapies for cancer, primarily L-DOS47 for non-small cell lung cancer and V-DOS47. With collaborations aimed at enhancing treatment efficacy, the company operates in a competitive biotechnology landscape with a small team of 7 employees.
What Is the Investment Thesis for HBPCF?
Helix BioPharma Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on immune-oncology, particularly the development of L-DOS47 and V-DOS47, addresses a significant unmet need in cancer treatment. Key value drivers include successful clinical trial outcomes and potential partnerships with larger pharmaceutical companies. The collaborations with Moffitt Cancer Center and University Hospital Tuebingen could accelerate drug development and validation. However, the company's small size and limited financial resources pose significant risks. The negative P/E ratio of -30.96 reflects the company's current lack of profitability. Successful navigation of clinical trials and securing additional funding are critical for the company's long-term success. Investors should closely monitor clinical trial results and partnership developments.
Based on FMP financials and quantitative analysis
HBPCF Key Highlights
Market capitalization of $131M, indicating a small-cap company with potential for growth.
- Negative P/E ratio of -30.96, reflecting the company's current lack of profitability and ongoing investment in research and development.
- Beta of -0.39, suggesting the stock is less volatile than the market, which may appeal to risk-averse investors.
- Focus on immune-oncology, a rapidly growing field with significant potential for innovative cancer therapies.
- Collaboration agreements with Moffitt Cancer Center and University Hospital Tuebingen, providing access to expertise and resources for drug development.
Who Are HBPCF's Competitors?
HBPCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACHFF Arch Biopartners Inc. | $0.71 | -10.69% | $48.2M | 38 |
| CLTEF Calliditas Therapeutics Ab | $0.18 | -0.39% | $10.8M | 45 |
| INNMF Amplia Therapeutics Limited | $0.10 | -8.70% | $53.9M | 48 |
| OTLC Oncotelic Therapeutics, Inc. | $0.04 | -7.26% | $17.1M | 38 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HBPCF's Key Strengths?
Innovative DOS47 platform targeting cancer cells.
- Collaboration agreements with reputable cancer research institutions.
- Focus on the rapidly growing field of immune-oncology.
- Patent protection for key drug candidates.
What Are HBPCF's Weaknesses?
Small size and limited financial resources.
- Dependence on successful clinical trial outcomes.
- Negative P/E ratio indicating lack of profitability.
- OTC market listing, which may limit investor access.
What Could Drive HBPCF Stock Higher?
Clinical trial results for L-DOS47 in non-small cell lung cancer, expected in late 2026.
- Collaboration with Moffitt Cancer Center to investigate L-DOS47 in combination with immune checkpoint inhibitors.
- Collaboration with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models.
- Potential strategic partnerships with larger pharmaceutical companies, anticipated in 2027.
- Regulatory submissions for L-DOS47, expected in 2028 if clinical trials are successful.
What Are the Key Risks for HBPCF?
Financial-distress signal — its Altman Z-Score of 1.49 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-21.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for L-DOS47 or V-DOS47.
- Competition from larger, more established pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Patent expirations and generic competition.
- Limited financial resources and dependence on additional funding.
What Are the Growth Opportunities for HBPCF?
- Expansion of L-DOS47 clinical trials: The primary growth opportunity lies in the successful completion and expansion of clinical trials for L-DOS47 in the treatment of non-small cell lung cancer. The timeline for this growth opportunity depends on the pace of clinical trial progress and regulatory review.
- Development of V-DOS47: The development of V-DOS47, targeting VEGFR2, represents another growth avenue. Successful preclinical and clinical development could lead to a new treatment option for cancers driven by angiogenesis. The market for anti-angiogenic therapies is substantial, offering significant revenue potential. The timeline for this growth opportunity is contingent on research and development progress and regulatory approvals.
- Strategic partnerships: Forming strategic partnerships with larger pharmaceutical companies could provide Helix BioPharma with access to additional funding, expertise, and distribution channels. These partnerships could accelerate the development and commercialization of its drug candidates. The potential market size would depend on the specific terms of the partnership and the target market for the partnered drug. The timeline for securing partnerships is uncertain but could occur in the near to medium term.
- Expansion into new cancer indications: Expanding the application of the DOS47 platform to other cancer indications represents a long-term growth opportunity. This would require further research and development, but could significantly broaden the company's market reach. The market size for new cancer indications would vary depending on the specific cancer type. The timeline for this growth opportunity is likely several years.
- Combination therapies: Investigating and developing combination therapies involving L-DOS47 and other cancer treatments, such as immune checkpoint inhibitors, could enhance treatment efficacy and expand the market opportunity. The collaboration with Moffitt Cancer Center is focused on exploring this potential. The market size for combination therapies is substantial, as they often provide improved outcomes compared to single-agent treatments. The timeline for this growth opportunity depends on the results of ongoing research and clinical trials.
What Are HBPCF's Competitive Advantages?
- Proprietary DOS47 platform: The DOS47 platform represents a unique approach to cancer therapy, providing a potential competitive advantage.
- Patent protection: Patents on L-DOS47 and V-DOS47 provide exclusivity and protect the company's intellectual property.
- Collaboration agreements: Collaborations with leading cancer research institutions enhance the company's credibility and provide access to valuable expertise and resources.
- Focus on immune-oncology: The focus on immune-oncology positions the company in a rapidly growing and innovative field.
What Does HBPCF Do?
Helix BioPharma Corp., headquartered in Toronto, Canada, is an immune-oncology company dedicated to developing innovative cancer therapies. The company's primary focus is on its DOS47 platform, which includes L-DOS47 for the treatment of non-small cell lung cancer (NSCLC) and V-DOS47, targeting the vascular epithelial growth factor receptor 2 (VEGFR2). These therapies are designed to leverage the body's immune system to fight cancer cells. Helix BioPharma collaborates with leading cancer research institutions such as Moffitt Cancer Center and University Hospital Tuebingen to advance the development and understanding of its drug candidates. These collaborations aim to investigate the pharmacodynamics of L-DOS47, determine the benefits of combining it with immune checkpoint inhibitors, and assess its therapeutic response in cancer models expressing CEACAM6, utilizing advanced preclinical metabolic imaging. The company's strategic approach involves targeting specific cancer pathways and utilizing innovative drug delivery methods to improve treatment outcomes. With a small team of 7 employees, Helix BioPharma operates in a highly competitive biotechnology sector, striving to make a significant impact in the field of cancer treatment.
What Products and Services Does HBPCF Offer?
- Develops L-DOS47 for the treatment of non-small cell lung cancer.
- Develops V-DOS47 that targets the vascular epithelial growth factor receptor 2.
- Conducts research and development in the field of immune-oncology.
- Collaborates with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47.
- Collaborates with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models.
- Focuses on targeted therapies to leverage the body's immune system to fight cancer cells.
How Does HBPCF Make Money?
- Develops and patents novel cancer therapies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through research grants and collaboration agreements.
- Seeks regulatory approval for its drug candidates.
What Industry Does HBPCF Operate In?
Helix BioPharma operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The immune-oncology segment, in particular, is experiencing rapid growth due to the increasing understanding of the role of the immune system in fighting cancer. Key trends include the development of personalized medicine, targeted therapies, and combination therapies. Helix BioPharma's focus on the DOS47 platform positions it within this innovative space, but it faces competition from larger, more established pharmaceutical companies with greater resources.
Who Are HBPCF's Key Customers?
- Cancer patients suffering from non-small cell lung cancer.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Research institutions and universities.
Key Financial Metrics
Return on equity for Helix BioPharma Corp. stands at -21.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.45 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.0%, the inverse of the P/E and a quick read on earnings relative to price.
Helix BioPharma Corp. (HBPCF) Valuation Context
Valued at $131M, HBPCF is classified as a micro-cap stock. Relative to its peer group, HBPCF's quantitative score of 45/100 is roughly in line with the peer average of 48/100.
Company Profile
Helix BioPharma Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Thomas Mehrling. HBPCF has traded publicly since 2009.
Financial Health
Helix BioPharma Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.49 places it in the distress zone, a signal of elevated financial risk.
HBPCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating potential growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approach to cancer treatment.
- Recent partnerships and collaborations have bolstered market perception, showcasing Helix's commitment to advancing its research.
- Increased media coverage has drawn attention to Helix's unique therapies, potentially attracting new investors.
Bear Case
- Concerns over regulatory hurdles could impact the timeline for product approvals, creating uncertainty for investors.
- Some community members express skepticism about the company's ability to compete with larger, established players in the biotech space.
- Recent clinical trial results have raised questions about the efficacy of their treatments, leading to cautious sentiment.
- Market volatility in the biotech sector may deter risk-averse investors from committing to Helix at this time.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HBPCF Latest News
No recent news available for HBPCF.
HBPCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HBPCF.
Price Targets
Wall Street price target analysis for HBPCF.
HBPCF MoonshotScore
What does this score mean?
The MoonshotScore rates HBPCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Thomas Mehrling
CEO
Thomas Mehrling serves as the CEO of Helix BioPharma Corp. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy and business development. He has held various leadership positions in companies involved in drug development and commercialization. His expertise lies in guiding companies through the complex process of bringing novel therapies to market, from preclinical research to regulatory approval and commercial launch.
Track Record: Under Thomas Mehrling's leadership, Helix BioPharma Corp. has focused on advancing its DOS47 platform and securing collaborations with leading cancer research institutions. Key milestones include the ongoing clinical trials for L-DOS47 and the partnerships with Moffitt Cancer Center and University Hospital Tuebingen. He is responsible for steering the company's strategic direction and overseeing its research and development efforts.
HBPCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Helix BioPharma Corp. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase investment risk. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited disclosure requirements on the OTC market.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable financial information.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Collaboration agreements with reputable cancer research institutions.
- Focus on innovative cancer therapies.
- Patent protection for key drug candidates.
- Presence of a management team with experience in the pharmaceutical industry.
- Ongoing clinical trials for L-DOS47.
What Investors Ask About Helix BioPharma Corp. (HBPCF) — Healthcare
What does the AI Score mean for HBPCF?
HBPCF holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Helix BioPharma Corp. is a Canadian immune-oncology company focused on developing L-DOS47 for non-small cell lung cancer and V-DOS47 targeting vascular epithelial growth factor receptor 2. …
What does Helix BioPharma Corp. do?
Helix BioPharma Corp. is a Canadian immune-oncology company focused on developing innovative cancer therapies. Its primary focus is on the DOS47 platform, which includes L-DOS47 for the treatment of non-small cell lung cancer (NSCLC) and V-DOS47, targeting the vascular epithelial growth factor receptor 2 (VEGFR2).
What do analysts say about HBPCF stock?
As of March 16, 2026, there is no readily available analyst consensus on HBPCF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-30.96), reflect the company's current lack of profitability and ongoing investment in research and development.
What are the main risks for HBPCF?
The main risks for Helix BioPharma Corp. include clinical trial failures, competition from larger pharmaceutical companies, regulatory hurdles, and limited financial resources. As a small-cap, OTC-listed company, HBPCF faces challenges in securing funding and navigating the complex regulatory landscape. The success of its drug candidates, particularly L-DOS47 and V-DOS47, is critical to its long-term viability.
What are the key factors to evaluate for HBPCF?
Helix BioPharma Corp. (HBPCF) holds an AI score of 45/100 (low). presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does HBPCF data refresh on this page?
HBPCF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HBPCF's recent stock price performance?
Helix BioPharma Corp. (HBPCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative DOS47 platform targeting cancer cells. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HBPCF overvalued or undervalued right now?
Helix BioPharma Corp. (HBPCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HBPCF before investing?
Before investing in Helix BioPharma Corp. (HBPCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 16, 2026.
- OTC market data may be limited or inconsistent.
- Analyst consensus may not be available for all OTC-listed companies.